Study title:
Schellong-G, Braemswig-J-H, Hoernig-Franz-I.
University Childrens Hospital, Department of Haematology and Oncology, Muenster, Germany. Pediatric Oncology Group.
Treatment of children with Hodgkin's disease-results of the German Pediatric Oncology Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, {Ann-Oncol}, Sep 1992, vol. 3 Suppl 4, p. 73-6, ISSN: 0923-7534.Schellong-G, Braemswig-J-H, Hoernig-Franz-I.
University Childrens Hospital, Department of Haematology and Oncology, Muenster, Germany. Pediatric Oncology Group.
Treatment of children with Hodgkin's disease-results of the German Pediatric Oncology Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, {Ann-Oncol}...
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Neoplasms [C04]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: PROCARBAZINE |
ATC code: |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
Y
|
-
|